The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).
 
Rohit K. Jain
Honoraria - Alphasights (I)
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Pfizer; Seattle Genetics/Astellas; Taiho Oncology (I)
Speakers' Bureau - Gilead Sciences; Seattle Genetics/Astellas
Research Funding - Bristol Myers Squibb
 
Youngchul Kim
No Relationships to Disclose
 
Jennifer Rembisz
No Relationships to Disclose
 
Richard Piekarz
No Relationships to Disclose
 
Timothy W. Synold
No Relationships to Disclose
 
Jingsong Zhang
Honoraria - AstraZeneca/MedImmune; Bayer; Clovis Oncology; Merck; Sanofi; Seagen
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Clovis oncology; Dendreon; Janssen Oncology; Myovant Sciences; Seagen
Speakers' Bureau - AstraZeneca; Merck Sharp & Dohme; Sanofi; Seagen; Seagen
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Bayer
 
Guru P. Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Infinity Pharmaceuticals; Janssen; Loxo/Lilly; Merck; Pfizer; Scholar Rock; Seagen
Speakers' Bureau - Medscape; Onclive; Physicans' Education Resource; Research to Practice
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Janssen (Inst); Predicine (Inst); QED Therapeutics (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bristol-Myers Squibb; Debiopharm Group; Elsevier; G1 Therapeutics; Mereo BioPharma; QED Therapeutics